BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/14/2023 7:03:17 AM | Browse: 297 | Download: 1277
 |
Received |
|
2022-10-24 08:23 |
|
Peer-Review Started |
|
2022-10-04 04:04 |
|
First Decision by Editorial Office Director |
|
2022-12-19 07:27 |
|
Return for Revision |
|
2022-12-19 07:27 |
|
Revised |
|
2023-01-08 10:24 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-01-20 03:13 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-01-20 05:54 |
|
Articles in Press |
|
2023-01-20 05:54 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-02-02 16:06 |
|
Publish the Manuscript Online |
|
2023-02-14 07:03 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Respiratory System |
| Manuscript Type |
Case Report |
| Article Title |
Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mei-Hong Liu, Yan-Xia Li and Zhuo Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Foundation of Science and Technology Bureau of Dalian |
2021JJ13SN70 |
|
| Corresponding Author |
Zhuo Liu, PhD, Doctor, Doctor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116011, Liaoning Province, China. liuzhuo@firstosp-dmu.com |
| Key Words |
Combined small cell lung cancer; Envafolimab; Carboplatin; Etoposide; Prognosis; Case report |
| Core Tip |
Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer, which is relatively rare, aggressive, prone to early metastasis, and has a poor prognosis. With the development and progress of immunotherapy, several clinical studies have shown that programmed death ligand-1 combined with chemotherapy can effectively prolong the progression-free survival and median overall survival of patients with extensive stage small cell lung cancer, but its efficacy in C-SCLC is not exact. In this paper, we report a patient with extensive stage C-SCLC who was treated with envafolimab combined with carboplatin and etoposide with preliminary anti-tumor activity, safety and tolerability. |
| Publish Date |
2023-02-14 07:03 |
| Citation |
Liu MH, Li YX, Liu Z. Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report. World J Clin Cases 2023; 11(5): 1115-1121 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i5/1115.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i5.1115 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
